

manipalhospitals

LIFE'S ON

TMT INVESTIGATION REPORT

Patient Name	MR KARAN KAKKAR	Location	: Ghaziabad
Age/Sex	: 44Year(s)/male	Visit No	: V000000001-GHZB
MRN No	MH010618997	Order Date	: 20/05/2024
Ref. Doctor	: HCP	Report Date	: 20/05/2024

Protocol Duration of exercise Reason for termination : THR achieved

: Bruce : 09min 30sec Blood Pressure (mmHg) : Baseline BP : 120/80mmHg Peak BP : 150/90mmHg

MPHR	: 176BPM
85% of MPHR	: 149BPM
Peak HR Achieved	: 163BPM
% Target HR	: 92%
METS	: 10.9METS

STAGE	TIME (min)	H.R (bpm)	BP (mmHg)	SYMPTOMS	ECG CHANGES	ARRHYTHMIA
PRE- EXC.	0:00	84	120/80	Nil	No ST changes seen	Nil
STAGE 1	3:00	101	130/90	Nil	No ST changes seen	Nil
STAGE 2	3:00	115	140/90	Nil	No ST changes seen	Nil
STAGE 3	3:00	147	150/90	Nil	No ST changes seen	Nil
STAGE 4	0:30	163	150/90	Nil	No ST changes seen	Nil
RECOVERY	3:14	97	130/80	Nil	No ST changes seen	Nil

COMMENTS:

- No ST changes in base line ECG. .
- No ST changes at peak stage. .
- No ST changes in recovery.
- Normal chronotropic response.
- Normal blood pressure response.

IMPRESSION:

Treadmill test is **negative** for exercise induced reversible myocardial ischemia.

Dr. Bhupendra Singh

MD, DM (CARDIOLOGY), FACC Sr. Consultant Cardiology

Dr. Abhishek Singh

MD, DNB (CARDIOLOGY), MNAMS Sr.Consultant Cardiology

Dr. Sudhanshu Mishra

Cardiology Registrar NH - 24, Hapur Road, Ghaziabad, Uttar Pradesh - 201 002 P: 0120-3535353

Dr. Geetesh Govil MD,D.Card,PGDDC,MAAC,M.Med,MIMA,FAGE Jr. Consultant Cardiology

Manipal Health Enterprises Private Limited CIN: U85110KA2003PTC033055 Regd. Off. The Annexe, #98/2, Rustom Bagh, Off. HAL Airport Road, Bengaluru - 560 017 P +91 80 4936 0300 E info@manipalhospitals.com www.manipalhospitals.com

Beneficiary Code-296425

Karan Kakkar < KARAN.KAKKAR@bankofbaroda.com>

Mon 5/20/2024 9:04 AM

To:PHC [MH-Ghaziabad] <phc.ghaziabad@manipalhospitals.com>

You don't often get email from karan.kakkar@bankofbaroda.com. Learn why this is important

Get Outlook for iOS

From: Mediwheel <wellness@mediwheel.in> Sent: Wednesday, May 1, 2024 16:50 To: Karan Kakkar <KARAN.KAKKAR@bankofbaroda.com> Cc: customercare@mediwheel.in <customercare@mediwheel.in> Subject: Health Check up Booking Confirmed Request(22E29095),Package Code-PKG10000476, Beneficiary Code-296425

यह मेल बैंक डोमेन के बाहर से आया है. अगर आप प्रेषक को नहीं जानते तो मेल में दी गयी लिंक पर क्लिक ना करें या I: THIS MAIL IS ORIGINATED FROM OUTSIDE OF THE BANK'S DOMAIN. DO NOT CLICK ON LINKS OR

011-41195959

Ì.

Dear Karan kakkar,

We are pleased to confirm your health checkup booking request with the following details.

Hospital Package Name	;	Mediwheel Full Body Health Checkup Male Above 40
Patient Package Name	:	Mediwheel Full Body Health Checkup Male Above 40
Name of Diagnostic/Hospital	:	Manipal Hospital
Address of Diagnostic/Hospital		NH-24,Hapur Road,Oppo. Bahmeta Village,Near Lancraft Golf Links Aparment
City	:	Ghaziabad
State	:	Uttar Pradesh
Pincode	:	201002
Appointment Date	:	20-05-2024
Confirmation Status	;	Booking Confirmed
Buchause al Time	,	0.20 am

Member Information							
Booked Member Name	Age	Gender					
MR. KAKKAR KARAN	44 year	Male					

Note - Please note to not pay any amount at the center.

Instructions to undergo Health Check:

- Please ensure you are on complete fasting for 10-To-12-Hours prior to check.
- During fasting time do not take any kind of medication, alcohol, cigarettes, tobacco or any other liquids (except Water) in the morning.
- Bring urine sample in a container if possible (containers are available at the Health Check centre).
- Please bring all your medical prescriptions and previous health medical records with you.
- Kindly inform the health check reception in case if you have a history of diabetes and cardiac problems.

For Women:

- Pregnant Women or those suspecting are advised not to undergo any X-Ray test.
- It is advisable not to undergo any Health Check during menstrual cycle.

Request you to reach half an hour before the scheduled time.

In case of further assistance, Please reach out to Team Mediwheel.

Thanks, Mediwheel Team Please Download Mediwheel App

You have received this mail because your e-mail ID is registered with Arcofemi Healthcare Limited This is a system-generated e-mail please don't reply to this message.

Please visit to our Terms & Conditions for more informaion. Click here to unsubscribe.

@ 2024 - 25, Accolemi Healthcare Pvt Limited.(Mediwheel)

including any

attachments) is intended for the sole use of the intended recipient/s and may contain material that is CONFIDENTIAL AND PRIVATE COMPANY INFORMATION. Any review or reliance by others or copying or distribution or forwarding of any or all of the contents in this message is STRICTLY PROHIBITED. If you are not the intended recipient, please contact the sender by email and delete all copies; your cooperation in this regard is



manipanospitais

LIFE'S ON 🎆

Manipal Hospital Ghaziabad NH-24, Hapur Road, Near Landcraft Golflinks, Ghaziabad 201 002 0120 3535 353 / +91 88609 45566



OUTPATIENT RECORD

Hospital No:	MH010618997
Name:	MR KARAN KAKKAAR
Doctor Name:	DR PRIYANKA THUKRAL
Date:	20/05/2024 09:20AM

Visit No: 018000083743 Age/Sex: 44 Yrs/Male Specialty: DENTAL MEDICINE MGD

Clinical examination:

STAINS ++ CAL ++ MISSING 14,24,35,44,45 OCCLUSAL CARIES 36, DEEP CARIES 13, SPACING WITH LOWER ANTERIORS.

Diagnosis: CHRONIC GEN PERIODONTITIS

Advice: ORAL PROPHYLAXIS RCT WITH 13

DR PRIYANKA THUKRAL

Name	:	MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	:	MH010618997	Lab No	:	202405003117
Patient Episode	:	H18000002219	Collection Date	:	20 May 2024 09:17
Referred By Receiving Date	: :	HEALTH CHECK MGD 20 May 2024 09:17	Reporting Date	:	20 May 2024 11:45

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL

THYROID PROFILE, Serum			Specimen Type : Serum
T3 – Triiodothyronine (ELFA)	1.020	ng/ml	[0.610-1.630]
T4 - Thyroxine (ELFA)	6.550	ug/ dl	[4.680-9.360]
Thyroid Stimulating Hormone	2.660	µIU/mL	[0.250-5.000]

NOTE :

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormones has no effect.

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hyperthyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

Page1 of 3

Name	:	MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	:	MH010618997	Lab No	:	202405003117
Patient Episode	:	H18000002219	Collection Date	:	20 May 2024 09:17
Referred By Receiving Date	: :	HEALTH CHECK MGD 20 May 2024 09:17	Reporting Date	:	20 May 2024 11:32

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL

Specimen Type : Serum

PROSTATE SPECIFIC ANTIGEN(PSA-Total):	3.340 #	ng/mL	[<2.500]
---------------------------------------	---------	-------	----------

Method :ELFA

Note :1. This is a recommended test for detection of prostate cancer along with Digital Recta Examination (DRE) in males above 50 years of age

damage caused by BPH, prostatitis, or prostate cancer may increase circulating PSA levels. 2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy

3. PSA levels may appear consistently elevated / depressed due to the interference by hetero antibodies & nonspecific protein binding

4. Immediate PSA testing following digital rectal examination, ejaculation, prostatic massag indwelling catheterization, and ultrasonography and needle biopsy of prostate is not recomme as they falsely elevate levels

5. PSA values regardless of levels should not be interpreted as absolute evidence of the pre or absence of disease. All values should be correlated with clinical findings and results of other investigations

6. Sites of Non - prostatic PSA production are breast epithelium, salivary glands, peri - urethral

& anal glands, cells of male urethra && breast mil

7. Physiological decrease in PSA level by 18% has been observed in hospitalized / sedentary patients either due to supine position or suspended sexual activity

Recommended Testing Intervals

- * Pre-operatively (Baseline)
- * 2-4 days post-operatively
- * Prior to discharge from hospital
- * Monthly follow-up if levels are high or show a rising trend

Page2 of 3

Name	:	MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	:	MH010618997	Lab No	:	202405003117
Patient Episode	:	H18000002219	Collection Date	:	20 May 2024 09:17
Referred By Receiving Date	:	HEALTH CHECK MGD 20 May 2024 09:17	Reporting Date	:	20 May 2024 11:47

BLOOD BANK

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL

Blood Group & Rh Typing (Agglutination by gel/tube technique) Specimen-Blood

Blood Group & Rh typing

B Rh(D) Positive

Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate / gel technique.

Page3 of 3

NOTE :

- Abnormal Values

-----END OF REPORT-----

Chaert

Dr. Charu Agarwal Consultant Pathologist



UNIT BIOLOGICAL REFERENCE INTERVAL

Name	: MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	: MH010618997	Lab No	:	202405003117
Patient Episode	: H18000002219	Collection Date	:	20 May 2024 09:17
Referred By Receiving Date	: HEALTH CHECK MGD: 20 May 2024 09:17	Reporting Date	:	20 May 2024 11:33

RESULT

TEST

HAEMATOLOGY

COMPLETE BLOOD COUNT (AUTOMATED))	SPECIMEN-EDTA Whole Blood				
RBC COUNT (IMPEDENCE)	4.74	millions/cumm	[4.50-5.50]			
HEMOGLOBIN	14.0	g/dl	[13.0-17.0]			
Method:cyanide free SLS-colorime	etry					
HEMATOCRIT (CALCULATED)	44.6	8	[40.0-50.0]			
MCV (DERIVED)	94.1	fL	[83.0-101.0]			
MCH (CALCULATED)	29.5	pg	[25.0-32.0]			
MCHC (CALCULATED)	31.4 #	g/dl	[31.5-34.5]			
RDW CV% (DERIVED)	13.1	8	[11.6-14.0]			
Platelet count	320	x 10 ³ cells/cumm	[150-410]			
Method: Electrical Impedance						
MPV (DERIVED)	9.40	fL				
WBC COUNT (TC) (IMPEDENCE) DIFFERENTIAL COUNT (VCS_TECHNOLOGY/MICBOSCOPY)	7.46	x 10 ³ cells/cumm	[4.00-10.00]			
Neutrophils	66.0	9	[40, 0-80, 0]			
Lymphocytes	25.0	9 9	[20.0-40.0]			
Monocytes	6.0	00	[2.0-10.0]			
Eosinophils	3.0	00	[1.0-6.0]			
Basophils	0.0	8	[0.0-2.0]			
ESR	16.0 #	mm/1sthour	[0.0-			

Page1 of 8



Name	: MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	: MH010618997	Lab No	:	202405003117
Patient Episode	: H18000002219	Collection Date	:	20 May 2024 09:18
Referred By Receiving Date	: HEALTH CHECK MGD : 20 May 2024 09:18	Reporting Date	e:	20 May 2024 10:16

CLINICAL PATHOLOGY

ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

MACROSCOPIC DESCRIPTION		
Colour	PALE YELLOW	(Pale Yellow - Yellow)
Appearance	CLEAR	
Reaction[pH]	5.0	(4.6-8.0)
Specific Gravity	1.025	(1.003-1.035)
CHEMICAL EXAMINATION		
Drotoin /Albumin	Nogativo	

Negative	(NEGATIVE)
NIL	(NIL)
Negative	(NEGATIVE)
Normal	(NORMAL)
	Negative NIL Negative Normal

MICROSCOPIC EXAMINATION (Automated/Manual)

Pus Cells	1-2 /hpf		(0-5/hpf)
RBC	NIL		(0-2/hpf)
Epithelial Cells	1-2	/hpf	
CASTS	NIL		
Crystals	NIL		
Bacteria	NIL		
OTHERS	NIL		

Page2 of 8



Age

Lab No :	202405003117
Collection Date :	20 May 2024 09:17
Reporting Date :	20 May 2024 13:58

: 44 Yr(s) Sex :Male

BIOCHEMISTRY

: MR KARAN KAKKAAR

: HEALTH CHECK MGD

: MH010618997

: H1800002219

: 20 May 2024 09:17

TEST		RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
Glycosyla Specimen: HbA1c (Gl Method: H	ted Hemoglobin EDTA ycosylated Hemoglobin) PLC	4.2	8	[0.0-5.6]
			As per A HbAlc Non di Predia Diagno	American Diabetes Association(ADA in % Labetic adults >= 18years <5.7 Abetes (At Risk)5.7-6.4 Diabetes >= 6.5
Estimated	Average Glucose (eAG)	74	mg/dl	

Comments : HbAlc provides an index of average blood glucose levels over the past $8{-}12$ weeks and is a much better indicator of long term glycemic control.

Serum LIPID PROFILE

Name

Registration No

Patient Episode

Receiving Date

Referred By

Serum TOTAL CHOLESTEROL	147	mg/dl	[<200]
Method:Oxidase,esterase, peroxide			Moderate risk:200-239
			High risk:>240
TRIGLYCERIDES (GPO/POD)	62	mg/dl	[<150]
			Borderline high:151-199
			High: 200 - 499
			Very high:>500
HDL- CHOLESTEROL	35	mg/dl	[35-65]
Method : Enzymatic Immunoimhibition			
VLDL- CHOLESTEROL (Calculated)	12	mg/dl	[0-35]
CHOLESTEROL, LDL, CALCULATED	100.0	mg/dl	[<120.0]
			Near/

Above optimal-100-129

Borderline High:130-159 High Risk:160-189

Page3 of 8



Name	: MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	: MH010618997	Lab No	:	202405003117
Patient Episode	: H18000002219	Collection Date	e:	20 May 2024 09:17
Referred By Receiving Date	: HEALTH CHECK MGD : 20 May 2024 09:17	Reporting Date	e:	20 May 2024 10:13

TEST	RESULT		UNIT	BIOLOGICAL REFERENCE INTERVAL
T.Chol/HDL.Chol ratio(Calculate	ed)	4.2		<4.0 Optimal 4.0-5.0 Borderline >6 High Risk
LDL.CHOL/HDL.CHOL Ratio(Calculat	ted)	2.9		<3 Optimal 3-4 Borderline >6 High Risk

Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

KIDNEY PROFILE

Specimen: Serum			
UREA	24.9	mg/dl	[15.0-40.0]
Method: GLDH, Kinatic assay			
BUN, BLOOD UREA NITROGEN	11.6	mg/dl	[8.0-20.0]
Method: Calculated			
CREATININE, SERUM	0.97	mg/dl	[0.70-1.20]
Method: Jaffe rate-IDMS Standardiz	zation		
URIC ACID	4.9	mg/dl	[4.0-8.5]
Method:uricase PAP			
		- /-	
SODIUM, SERUM	137.90	mmol/L	[136.00-144.00]
POTASSIUM, SERUM	4.42	mmol/L	[3.60-5.10]
SERUM CHLORIDE	107.0	mmol/L	[101.0-111.0]
Method: ISE Indirect			

Page4 of 8



Name	: MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	: MH010618997	Lab No	:	202405003117
Patient Episode	: H18000002219	Collection Date	:	20 May 2024 09:17
Referred By Receiving Date	: HEALTH CHECK MGD: 20 May 2024 09:17	Reporting Date	:	20 May 2024 10:13

TEST	RESULT	UNIT	BIOLOGICAL	REFERENCE INTERVAL
eGFR (calculated) Technical Note	94.5	ml/min/1	L.73sq.m	[>60.0]

eGFR which is primarily based on Serum Creatinine is a derivation of CKD-EPI 2009 equation normalized to1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g. patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis Icterus / Lipemia.

LIVER FUNCTION TEST

BILIRUBIN - TOTAL Method: D P D	0.76	mg/dl	[0.30-1.20]
BILIRUBIN - DIRECT Method: DPD	0.18	mg/dl	[0.00-0.30]
INDIRECT BILIRUBIN(SERUM) Method: Calculation	0.58	mg/dl	[0.10-0.90]
TOTAL PROTEINS (SERUM) Method: BIURET	6.90	gm/dl	[6.60-8.70]
ALBUMIN (SERUM) Method: BCG	4.39	g/dl	[3.50-5.20]
GLOBULINS (SERUM) Method: Calculation	2.50	gm/dl	[1.80-3.40]
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.75		[1.00-2.50]
AST(SGOT) (SERUM) Method: IFCC W/O P5P	24.00	U/L	[0.00-40.00]



Name	: MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	: MH010618997	Lab No	:	202405003117
Patient Episode	: H18000002219	Collection Date	:	20 May 2024 09:17
Referred By Receiving Date	: HEALTH CHECK MGD: 20 May 2024 09:17	Reporting Date	:	20 May 2024 10:13

TEST	RESULT	UNIT	BIOL	OGICAL REFERENCE INTER	RVAL
ALT(SGPT) (SERUM) Method: IFCC W/O P5P	24.50	Ţ	1/L	[17.00-63.00]	
Serum Alkaline Phosphatase Method: AMP BUFFER IFCC)	81.0	1	U/L	[32.0-91.0]	
GGT	31.0		U/L	[7.0-50.0]	

Liver function test aids in diagnosis of various pre hepatic, hepatic and post hepatic causes of dysfunction like hemolytic anemia's, viral and alcoholic hepatitis and cholestasis of obstructive causes.

The test encompasses hepatic excretory, synthetic function and also hepatic parenchymal cell damage. LFT helps in evaluating severity, monitoring therapy and assessing prognosis of liver disease and dysfunction.

Page6 of 8

------END OF REPORT------

flagent

Dr. Charu Agarwal Consultant Pathologist



Name	: MR KARAN KAKKAAR	Age	:	44 Yr(s) Sex :Male
Registration No	: MH010618997	Lab No	:	202405003118
Patient Episode	: H18000002219	Collection Date	:	20 May 2024 09:17
Referred By Receiving Date	: HEALTH CHECK MGD : 20 May 2024 09:17	Reporting Date	:	20 May 2024 10:13

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
GLUCOSE-Fasting			
Specimen: Plasma			

GLUCOSE,	FASTING (F)	103.0	mg/dl	[70.0-110.0]
Method:	Hexokinase			

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortica insufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases(e.g.galactosemia), Drugs-

insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

-----END OF REPORT-----

Page7 of 8

flagent

Dr. Charu Agarwal Consultant Pathologist



: MR KARAN KAKKAAR	Age :	44 Yr(s) Sex :Male
: MH010618997	Lab No :	202405003119
: H18000002219	Collection Date :	20 May 2024 11:32
: HEALTH CHECK MGD	Reporting Date :	20 May 2024 12:17

BIOCHEMISTRY

Name

Registration No Patient Episode **Referred By Receiving Date**

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERVAL
PLASMA GLUCOSE Specimen:Plasma GLUCOSE, POST PRANDIAL (PP), <i>Method: Hexokinase</i> Note: Conditions which can lead to	2 HOURS 117.0	mg/dl	[80.0-140.0]
fasting glucose are excessive brisk glucose absorption , po	insulin release, st exercise	rapid gastric	e emptying,

Page8 of 8

-----END OF REPORT------

Charl

Dr. Charu Agarwal **Consultant Pathologist**